12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LDMP: Phase III data

Hisamitsu's Noven Pharmaceuticals Inc. subsidiary reported top-line data from a double-blind, U.S. Phase III trial in menopausal women showing that once-daily LDMP for 12 weeks met the co-primary endpoints of reducing the mean frequency and severity of moderate to severe hot flashes from baseline to week 4 vs. placebo....

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >